DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Interstitial Cystitis - Pipeline Review, H1 2017" report to their offering.
Pharmaceutical and Healthcare latest pipeline guide Interstitial Cystitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 6, 1, 6 and 1 respectively.
Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Report Coverage
- Interstitial Cystitis (Painful Bladder Syndrome) - Overview
- Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Interstitial Cystitis (Painful Bladder Syndrome) - Companies Involved in Therapeutics Development
- Allergan Plc
- Aquinox Pharmaceuticals Inc
- Astellas Pharma Inc
- BELLUS Health Inc
- Kytogenics Pharmaceuticals Inc
- Lipella Pharmaceuticals Inc
- Merck & Co Inc
- UCB SA
- Urigen Pharmaceuticals Inc
For more information about this report visit http://www.researchandmarkets.com/research/7qs9zt/interstitial